Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more.

Choose a location

    Mildness: Non-irritating excipients for compromised, diseased or wounded skin applications

    A selection of excipients that are proven to be mild and non-irritating in highly sensitive in in vitro cell culture studies and in in vivo clinical studies.

    Formulators and scientists who are developing products to treat acne, rosacea, eczema, psoriasis, wounds and other compromised skin states, must utilize mild and inert excipients or risk exacerbation of the treated conditions. BASF is committed to continually evaluating our portfolio to proactively demonstrate that we have the mild materials that formulators need. By using cell culture test methods such as the Trans-Epithelial Permeation assay and on-going clinical patch tests on highly sensitive, allergy-prone patients, we are demonstrating that many of our excipients are inert and do not induce irritation. We offer a range non-irritating excipients proven to be ultra-mild on patients with sensitive skin and in highly sensitive in vitro tests. Examples include Kollicream® 3C (Cocoyl caprylocaprate), Kolliphor P 188® (Poloxamer 188), Kolliphor® TPGS (D-alpha tocopherol polyethylene glycol 1000 succinate), Kolliphor® PS 60 (Polysorbate 60) and Soluplus® (Polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol graft copolymer).

    Mildness is key for us
    Proven to be ultra-mild on sensitive skin
    High quality excipients for maximum mildness


    Mildness of Dermal Excipients as Determined by In Vivo Clinical Patch Tests

    The objective of these studies was to determine the allergy and irritation potential of oleochemical-based excipients that BASF markets for pharmaceutical dermal applications (e.g. creams, ointments, gels, foams, etc.), by clinical patch testing on patients who are being screened for allergies due to chronic episodes of dermatitis.